These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30865026)

  • 21. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
    Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
    J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.
    Spear TT; Wang Y; Smith TW; Simms PE; Garrett-Mayer E; Hellman LM; Baker BM; Nishimura MI
    Mol Ther; 2018 Apr; 26(4):996-1007. PubMed ID: 29503203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.
    Heemskerk MH; Hagedoorn RS; van der Hoorn MA; van der Veken LT; Hoogeboom M; Kester MG; Willemze R; Falkenburg JH
    Blood; 2007 Jan; 109(1):235-43. PubMed ID: 16968899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
    Akatsuka Y
    Front Immunol; 2020; 11():257. PubMed ID: 32184779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
    Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
    Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
    Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
    Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells.
    Voss RH; Thomas S; Pfirschke C; Hauptrock B; Klobuch S; Kuball J; Grabowski M; Engel R; Guillaume P; Romero P; Huber C; Beckhove P; Theobald M
    Blood; 2010 Jun; 115(25):5154-63. PubMed ID: 20378753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.
    Aggen DH; Chervin AS; Schmitt TM; Engels B; Stone JD; Richman SA; Piepenbrink KH; Baker BM; Greenberg PD; Schreiber H; Kranz DM
    Gene Ther; 2012 Apr; 19(4):365-74. PubMed ID: 21753797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.
    Circosta P; Granziero L; Follenzi A; Vigna E; Stella S; Vallario A; Elia AR; Gammaitoni L; Vitaggio K; Orso F; Geuna M; Sangiolo D; Todorovic M; Giachino C; Cignetti A
    Hum Gene Ther; 2009 Dec; 20(12):1576-88. PubMed ID: 19678763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.
    Wang QJ; Hanada K; Feldman SA; Zhao Y; Inozume T; Yang JC
    J Immunol Methods; 2011 Mar; 366(1-2):43-51. PubMed ID: 21255579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
    Jensen MC; Riddell SR
    Immunol Rev; 2014 Jan; 257(1):127-44. PubMed ID: 24329794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific roles of each TCR hemichain in generating functional chain-centric TCR.
    Nakatsugawa M; Yamashita Y; Ochi T; Tanaka S; Chamoto K; Guo T; Butler MO; Hirano N
    J Immunol; 2015 Apr; 194(7):3487-500. PubMed ID: 25710913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixed T cell receptor dimers harbor potentially harmful neoreactivity.
    van Loenen MM; de Boer R; Amir AL; Hagedoorn RS; Volbeda GL; Willemze R; van Rood JJ; Falkenburg JH; Heemskerk MH
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10972-7. PubMed ID: 20534461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
    Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
    Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of human islet-specific regulatory T cells by TCR gene transfer.
    Hull CM; Nickolay LE; Estorninho M; Richardson MW; Riley JL; Peakman M; Maher J; Tree TI
    J Autoimmun; 2017 May; 79():63-73. PubMed ID: 28117148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function.
    Schober K; Müller TR; Gökmen F; Grassmann S; Effenberger M; Poltorak M; Stemberger C; Schumann K; Roth TL; Marson A; Busch DH
    Nat Biomed Eng; 2019 Dec; 3(12):974-984. PubMed ID: 31182835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploitation of CD3ζ to enhance TCR expression levels and antigen-specific T cell function.
    Degirmencay A; Thomas S; Holler A; Burgess S; Morris EC; Stauss HJ
    Front Immunol; 2024; 15():1386132. PubMed ID: 38873603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
    Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
    J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain.
    Kuball J; Hauptrock B; Malina V; Antunes E; Voss RH; Wolfl M; Strong R; Theobald M; Greenberg PD
    J Exp Med; 2009 Feb; 206(2):463-75. PubMed ID: 19171765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.